Hypoplastic Left Heart Syndrome Treatment Integrates Cardiac Stem Cells.

Initial trials of stem cell treatment for hypoplastic left heart syndrome have proven to be both safe and effective for children with the congenital defect.

Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell.  In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition.

Children born with HLHS may die if they do not receive immediate surgery within a few days of birth, as well as long term treatments thereafter.  While further research is necessary to determine the full applicability of the procedure, the children’s own cardiac stem cells may hold the key to providing children born with HLHS with a higher quality of life.

As per Okayama University’s research, younger stem cells are preferred over older ones for medical therapies due to their higher regenerative abilities.  One way to assure access to the enhanced regenerative abilities of your own stem cells is to preserve them while they are still young, so that they can be used later in life in emerging regenerative therapies. Today, preserving your own stem cells, also known as autologous stem cells, is simple and affordable for families. To learn how you can preserve your own valuable stem cells through non-invasive and effective methods, please visit StemSave or call 877-783-6728 (877-StemSave) today.

 

 

To view the full article, click here.

To read the complete research article, click here.

 

 

The Future of Regenerative Medicine is Now™.